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Abstract
According to the 2018 Annual Report of the American Association of Poison
Control Centers (AAPCC), published in 2019, the most common cause of poisoning
was medicines in all human exposures. According to the data in this report, the
most common group of drugs that cause poisoning in humans are analgesics. The
first three drugs that cause poisoning among analgesics are fentanyl, acetamino-
phen, and oxycodone, respectively. Fentanyl and oxycodone are analgesic drugs
with an opioid nature. Opioid analgesics are the drugs of choice for acute and
chronic pain management, but after repeated exposure, they cause addiction as a
result of stimulation in the brain reward center, are used in higher doses to achieve
the same effect, and lead to withdrawal syndrome when medication is not taken.
Acetaminophen, which takes the second place in analgesic-related poisoning, is a
non-opioid analgesic and antipyretic drug. Acetaminophen is often found in hun-
dreds of over-the-counter (OTC) medications. In addition to being an OTC drug,
acetaminophen often causes poisoning as it is cheap and easily accessible. This
chapter reviews pharmacological properties of fentanyl, acetaminophen, and
oxycodone, in addition to poisoning signs and treatments.
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1. Introduction
Poisoning is a medical emergency representing a major health problem world-
wide, and the rate of poisoning of both prescription and over-the-counter (OTC)
drugs is increasing day by day [1]. According to the American Association of Poison
Control Centers (AAPCC) 2018 Annual Report, the most common cause of drug
poisonings was analgesics in all human exposures [2]. Analgesics are used to man-
age mild, moderate, and severe, as well as acute and chronic, pain [3]. Generally,
opioid and non-opioid drugs are used for analgesia [3]. According to the AAPCC
2018 Annual Report, most frequent causes of analgesic poisoning are fentanyl,
acetaminophen, and oxycodone, respectively [2]. Fentanyl and oxycodone are
opioid analgesics, whereas acetaminophen is a non-opioid analgesic [3].
Opioids are potent analgesics, but their use is limited as they cause addiction,
withdrawal, and tolerance [4]. Opioids exert their effects by stimulating classical
opioid receptors [μ (mu), δ (delta), and κ (kappa)] that are widely distributed in
the body [5, 6]. These receptors show seven transmembrane domain structures
specific to G-protein-coupled receptors, are induced by morphine and antagonized
by naloxone (NLX), and had similar analgesic effect [4]. According to the studies,
μ receptor was also related with addiction [7]. Opioid addiction develops in both
psychic and physical dependence [4]. After physical dependence development,
opioid consumption is maintained to prevent withdrawal symptoms [4]. Treatment
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of opioid addiction is long and difficult. For this purpose, opioid agonists, such as
methadone and buprenorphine, an opioid antagonist naltrexone, or abstinence-
based treatment may be preferred [8]. This disease, referred to as “opioid abuse and
opioid dependence” in the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSMIV-TR), has been changed to “opioid use dis-
order” in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) [9].
Classical opioid receptors are distributed in the peripheral tissue as well as
central nervous system (CNS) [4]. Stimulation of these receptors in the central
nervous system results in analgesia, drowsiness, euphoria, a sense of detachment,
respiratory depression, nausea and vomiting, depressed cough reflex, and hypo-
thermia [4]. When these receptors are stimulated in peripheral tissues, miosis,
orthostatic hypotension, constipation, urinary retention, etc. emerge [4]. After
stimulation of these Gi/0-coupled opioid receptors, the adenylate cyclase enzyme is
suppressed, and the level of cyclic AMP decreases [4]. In addition, the voltage-gated
calcium channels in the axon ends or neuron soma are closed, and intracellular
calcium levels are reduced, and potassium channels are opened, leading to an
increase in potassium conductance [4]. As a result, inhibition and hyperpolarization
of neurons occur when opioid receptors are stimulated [10, 11]. Analgesic or
antinociceptive effects, which are indicated for use of opioids, develop at the level
of the brain and spinal cord [12]. At the brain level, attenuation of impulse spread is
weakened and the perception of pain is inhibited, and at the spinal cord level, the
transmission of pain impulses is suppressed [12].
Non-opioid or non-steroidal anti-inflammatory drugs (NSAIDs) are used to
manage mild and moderate pain, as well as to reduce fever [13]. Although NSAIDs
exact mechanism of action has not been fully established, according to the previous
studies, it inhibits the cyclooxygenase pathways, which are involved in prostaglan-
din synthesis [14]. Prostaglandins are responsible for eliciting pain sensations [14].
NSAIDs do not cause addiction and withdrawal like opioid analgesics, and tolerance
to analgesic effect does not develop [13].
Poisoning may lead to more dangerous consequences when taking more than
one medication [2]. It is due to pharmacokinetic (PK) and pharmacodynamic
(PD) drug-drug interactions (DDIs). According to Lexicomp, there are five DDI
types (Table 1), which are clinically important (X, D, and C) and insignificant
(B and A) [15].
DDI
types
Approach Explanation
X Avoid combination The risks associated with simultaneous use of this drug outweigh the
benefits. Simultaneous use of this drug is contraindicated
D Consider therapy
modification
The rate of benefit and risk due to simultaneous use of this drug needs to
be evaluated, and aggressive monitoring of the patient, empirical dosage
changes, or selection of alternative agents should be considered
C Monitor therapy The benefits associated with simultaneous use of this drug outweigh the
risks, and dosage adjustments of one or both drugs may be considered
B No action needed No intervention required
A No known
interaction
No intervention required
Table 1.
DDI types and treatment approach [15].
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2. Analgesics that often lead to poisoning
2.1 Fentanyl
International Union of Pure and Applied Chemistry (IUPAC) name: N-phenyl-
N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Fentanyl is a synthetic and lipophilic phenylpiperidine opioid agonist with
molecular formula C22H28N20 and a molecular weight of 336.5 g/mol [16]. Fentanyl,
100 times more potent than morphine, was developed in the 1950s and approved by
the FDA in 1968 [17]. Fentanyl is used for pain management, induction and main-
tenance of general anesthesia, recovery from general or regional anesthesia, and
analgesia and sedation in intensive care unit patients [18–20]. It is applied by
injection (i.v., i.m., epidural, intrathecal), transdermal (device and patch),
transmucosal (buccal film and tablet, sublingual spray and tablet, lozenge), and
intranasal means [16]. Pharmacodynamics and pharmacokinetics are summarized
in Table 2.
Adverse effects (Table 3) occur when serum fentanyl concentration rises above
2 ng/mL [16]. CNS depression occurs above 3 ng/mL, whereas profound respiratory
depression usually occurs at concentrations of 10 to 20 ng/mL [16].
Since it is an opioid drug, fentanyl has the potential for abuse [4]. As mentioned
above, with repeated use of fentanyl, tolerance develops, which allows higher doses
to achieve the same effect [4]. Therefore, fentanyl can be administered at toxic
doses when abused. In addition, toxicity may develop with fentanyl used for thera-
peutic purposes [2]. These usually occur after accidental ingestion, following use in
opioid non-tolerant patients and improper dosing [2]. Known and expected adverse
reactions occur more severely, whether administered for abuse or therapeutic pur-
poses [16]. The most important of these is respiratory depression, which can have
fatal consequences. Concomitant use of fentanyl with drugs inhibiting CYP3A4
(e.g., erythromycin, ketoconazole, voriconazole, ritonavir) may cause potentially
fatal respiratory depression (Table 4). Fentanyl may be associated with the devel-
opment of serotonin syndrome. This risk increases when used concomitantly with
PDs and PKs Routes of administration
Intranasal i.m. i.v. Transdermal patch Transmucosal
Onset of action 5–10 min 7–8 min Immediately 6 h 5–15 min
Duration — 1–2 h 0.5–1 h 72–96 h —
Absorption — — — 12–24 h Rapidly
Distribution — — 4 L/kg — 25.4 L/kg
Protein binding Alpha-1-acid glycoprotein (mainly), albumin, and erythrocytes
Metabolism In the liver (primarily via CYP3A4) and intestinal mucosa
• n-Dealkylation to norfentanyl (active metabolite)
• Amide hydrolyzation to despropionylfentanyl
• Alkyl hydroxylation to hydroxyfentanyl
Bioavailability 64% 50–76%
Half-life elimination 15–25 h Adults: 2–4 h
Children: 2.4–36 h
20–27 h 3–14 h
Excretion • Urine (primarily)
• Feces
Table 2.
PDs and PKs of fentanyl at therapeutic doses [16, 21–23].
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drugs at risk of serotonin syndrome (Table 4). Population that are particularly at
risk and need attention are children; geriatric, cachectic, or debilitated patients; and
patients with renal and hepatic impairment, underlying pulmonary conditions,
known or suspected paralytic ileus and gastrointestinal obstruction, mucositis
(sublingual spray), and cardiac bradyarrhythmias [16]. Clinically important DDIs
are summarized in Table 4.
2.2 Acetaminophen
IUPAC name: N-(4-hydroxyphenyl)acetamide
Acetaminophen is an NSAID with molecular formula C8H9NO2 and a molecular
weight of 151.16 g/mol and approved by the FDA in 1951 [27]. Acetaminophen is
used by oral, injection (i.v.), and rectal means for mild to moderate pain
Systems Symptoms
CNS Confusion, dizziness, drowsiness, fatigue, headache, sedation, abnormal dreams,
abnormal gait, abnormality in thinking, agitation, altered sense of smell,
amnesia, anxiety, ataxia, chills, depression, disorientation, euphoria,
hallucination, hypertonia, hypoesthesia, hypothermia, insomnia, irritability, lack
of concentration, lethargy, malaise, mental status changes, neuropathy,
paranoia, paresthesia, restlessness, speech disturbance, stupor, vertigo,
withdrawal syndrome
Respiratory Dyspnea, atelectasis, cough, epistaxis, hemoptysis, flu-like symptoms,
wheezing, hyperventilation/hypoventilation, pharyngolaryngeal pain, rhinitis,
sinusitis, nasopharyngitis, pharyngitis, laryngitis, bronchitis, asthma,
pneumonia, nasal discomfort, postnasal drip, rhinorrhea
Cardiovascular Arrhythmia, pulmonary embolism (intranasal), chest pain, palpitations, deep
vein thrombosis, hypertension/hypotension, myocardial infarction, edema
Gastrointestinal
(GI)
Constipation, nausea, vomiting, abdominal distention, abdominal pain,
anorexia, decreased appetite, diarrhea, dysgeusia, dyspepsia, flatulence,
gingivitis, glossitis, stomatitis, tongue disease, xerostomia, gastroesophageal
reflux, gastritis, gastroenteritis, hemorrhage, ulcer, hematemesis, intestinal
obstruction, rectal pain
Hepatic Ascites, increased serum alkaline phosphatase, increased serum AST, jaundice
Genitourinary
(GU)
Renal failure, urinary retention, dysuria, erectile dysfunction, mastalgia, urinary
incontinence, urinary tract infection, urinary urgency, vaginal hemorrhage,
vaginitis
Ophthalmic Blepharoptosis, blurred vision, diplopia, strabismus, swelling and drying of eye,
visual disturbance
Hematologic and
oncologic
Anemia, leukopenia, neutropenia, thrombocytopenia, lymphadenopathy
Dermatologic Alopecia, cellulitis, decubitus ulcer, diaphoresis, erythema, hyperhidrosis, night
sweats, pallor, pruritus, skin rash
Endocrine and
metabolic
Dehydration, hot flash, hypercalcemia/hypocalcemia, hypokalemia,
hypomagnesemia, hyponatremia, hypoalbuminemia, hyperglycemia, weight loss
Neuromuscular and
skeletal
Asthenia, arthralgia, back pain, lower limb cramp, limb pain, myalgia, tremor
Miscellaneous Hypersensitivity reaction, fever, abscess
Table 3.
Common adverse reactions of fentanyl [16, 21–26].
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management and reduction of fever [27]. Acetaminophen is often found in hun-
dreds of OTC and prescription medicines [28]. PDs and PKs are summarized in
Table 5.
95% of acetaminophen undergoes biotransformation, while 5% is excreted
unchanged into the urine [29]. Approximately 45–55% of acetaminophen trans-
forms into glucuronide conjugates via UDP-glucuronosyltransferase, 30–35% into
sulfate conjugates via sulfotransferase, and only 5% into toxic metabolite NAPQI
Possible effects Clinically important DDI types
X D C
Increase in the
CNS depressant
effects
Azelastine,
bromperidol,
orphenadrine,
oxomemazine,
paraldehyde,
thalidomide,
mifepristone
Blonanserin,
chlormethiazole, CNS
depressants, droperidol,
flunitrazepam,
lemborexant, meperidine,
methotrimeprazine, opioid
agonists, oxycodone,
perampanel,
phenobarbital, primidone,
sodium oxybate,
suvorexant, zolpidem,
tramadol, tricyclic
antidepressants (TCA),
CYP3A4 inhibitors (strong,
moderate)
Ethanol, alizapride,
dimethindene,
brimonidine, bromopride,
tetrahydrocannabinol,
cannabidiol, Cannabis,
chlorphenesin carbamate,
dronabinol, lisuride,
lofexidine, magnesium
sulfate, metoclopramide,
minocycline (systemic),
nabilone, piribedil,
pramipexole, ropinirole,
rotigotine, rufinamide
Enhancement in
the serotonergic
effects and
serotonin
syndrome
Dapoxetine, monoamine
oxidase inhibitors
(MAOI)
Linezolid, meperidine,
methylene blue,
nefazodone, ozanimod,
tramadol, TCA
Almotriptan, alosetron,
amphetamines, antiemetics
(5HT3 antagonists),
dexmethylphenidate-
methylphenidate,
dextromethorphan,
eletriptan, ergot
derivatives, buspirone,
lorcaserin, ondansetron,
oxitriptan, ramosetron,
selective serotonin reuptake
inhibitors (SSRI), serotonin
5-HT1D receptor agonists
(triptans), serotonin/
norepinephrine reuptake
inhibitors (SNRI), St John’s
wort, Syrian rue
Constipation Eluxadoline — Anticholinergic agents,
ramosetron
Urinary
retention
— — Anticholinergic agents
Enhancement in
the bradycardia
effects
Fexinidazole Ceritinib, siponimod Bradycardia-causing agents,
ivabradine, lacosamide,
midodrine, ruxolitinib,
succinylcholine,
terlipressin, tofacitinib
Enhancement in
the psychomotor
impairment
— — SSRI
Table 4.
Fentanyl and clinically important DDIs [15].
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through the CYP2E1 (Figure 1) [32–34]. NAPQI, produced in small amounts in
therapeutic dose intakes, and hepatic glutathione are immediately transformed into
nontoxic cysteine and mercapturate metabolites via glutathione S-transferase and
excreted into the urine [34]. With intakes above the maximum daily dose (4 g in
adults and 75 mg/kg in children), the increased formation of NAPQI depletes
hepatic glutathione, covalently binds to critical cellular proteins and other vital
molecules, and thereby causes acute liver toxicity (hepatic damage, liver failure) or
PDs and PKs Routes of administration
Oral i.v.
Onset of action Above 1 h 5–10 min
Duration 4–6 h 4–6 h
Absorption Small intestine (primarily) and stomach
Distribution Adults: 4–6 L/kg
Children: 5–30 L/kg
Protein binding 10–25%
Metabolism In the liver
• Metabolism to glucuronide and sulfate conjugates (primarily)
By CYP2E1 to toxic intermediate, N-acetyl-p-benzoquinone imine (NAPQI,
Figure 1)
Bioavailability 88%
Half-life elimination Adults: 2–3 h
Children: 4–10 h
Excretion Urine (mainly)
Table 5.
PDs and PKs of acetaminophen at therapeutic doses [29–31].
Figure 1.
Metabolism of acetaminophen. NAPQI, N-acetyl-p-benzoquinone imine; (1) UDP-glucuronosyltransferase
(1-9, 1-6, 1-1, and 2B15 isoforms); (2) CYP2E1; (3) sulfotransferase (1A1 and 1A3/1A4 isoforms) and bile
salt sulfotransferase; (4) glutathione S-transferase (P and theta-1 isoforms) [33–35].
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even death [29, 35, 36]. Additional mechanisms such as mitochondrial injury, oxy-
gen, and nitrogen stress deepen hepatic cell damage [37].
Mild to moderate elevations in serum aminotransferase (aspartate aminotrans-
ferase, alanine aminotransferase) levels are the first sign of liver damage; some-
times it can even occur in chronic treatment at the maximum daily dose [35, 36].
These elevations are generally asymptomatic and resolve rapidly with stopping
therapy or reducing the dosage [35] and most commonly arise after taking more
than 7.5 g as a single overdose [38]. If hepatotoxicity is not too severe, serum
aminotransferase levels fall promptly, and recovery is rapid [39]. Instances of
unintentional overdose in children are often due to errors in calculating the correct
dosage or use of adult-sized tablets instead of child or infant formulations [39].
Concomitant use of acetaminophen (single) and acetaminophen-containing (com-
bined) products may also cause toxicity [39]. Acetaminophen overdose may be
manifested by renal tubular necrosis, hypoglycemic coma, and thrombocytopenia
[39]. Acetaminophen has been associated with a risk of rare but serious skin reac-
tions. These are Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute
generalized exanthematous pustulosis, and they can be fatal [39, 40]. Population
that are particularly at risk and need attention are children, since they have less
glucuronidation capacity of the drug than adults, and patients with alcoholism,
hepatic impairment or active hepatic disease, chronic malnutrition, severe
hypovolemia, and severe renal impairment [29, 38]. Adverse reactions and
clinically important DDIs of acetaminophen are summarized in Tables 6 and 7,
respectively.
2.3 Oxycodone
IUPAC name: (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-
2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
Systems Symptoms
CNS Trismus, fatigue, headache, agitation, anxiety, insomnia
Respiratory Atelectasis, hypoxia, pleural effusion, pulmonary edema, stridor, wheezing
Cardiovascular Tachycardia, hypertension/hypotension, edema
GI Constipation, nausea, vomiting, abdominal pain, diarrhea
Hepatic Increased serum transaminases, hyperbilirubinemia
GU Nephrotoxicity, hyperammonemia, oliguria
Ophthalmic Periorbital edema
Hematologic and
oncologic
Anemia
Dermatologic Pruritus, skin rash
Endocrine and
metabolic
Hypocalcemia, hyponatremia, hypokalemia, hypomagnesemia,
hypophosphatemia, hyperchloremia, low bicarbonate levels, hypoalbuminemia,
hyperuricemia, hyperglycemia, hypervolemia
Neuromuscular and
skeletal
Muscle spasm, limb pain
Miscellaneous Hypersensitivity reaction, fever
Table 6.
Common adverse reactions of acetaminophen [29, 38, 39].
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Oxycodone is a semisynthetic opioid agonist, produced from thebaine and
codeine found in the raw Papaver somniferum L. plant and approved by the FDA in
1968, with molecular formula C18H21NO4 and a molecular weight of 315.4 g/mol
[41–43]. It is used alone or in combination with acetaminophen in the management
of moderate to severe pain [3]. It binds to classical opioid receptors such as fentanyl
and mediates similar mechanisms of action [6]. Oxycodone also inhibits the release
of vasopressin, somatostatin, insulin, and glucagon and nociceptive neurotransmit-
ters, such as substance P, GABA, dopamine, acetylcholine, and noradrenaline [44].
The analgesic effects of oxycodone are mediated by both itself and its active
metabolites, noroxycodone, oxymorphone, and noroxymorphone [21]. It can be
applied both orally and rectally. PDs and PKs are summarized in Table 8.
Toxic effects occur when the serum oxycodone concentration is approximately
0.69 mg/L in single oxycodone administration and 0.72 mg/L in the oxycodone-
combined drug administration [50]. When the serum oxycodone concentration is
Possible effects Clinically important DDI types
X D C
Hepatotoxicity — Dasatinib,
sorafenib,
probenecid
Ethanol, barbiturates, carbamazepine, imatinib,
mipomersen, fosphenytoin-phenytoin, isoniazid,
metyrapone
Methemoglobinemia — — Dapsone, local anesthetics, nitric oxide, prilocaine,
sodium nitrite
High anion gap
metabolic acidosis
— — Flucloxacillin
Enhancement in the
anticoagulant effects
— — Vitamin K antagonists
Table 7.
Acetaminophen and clinically important DDIs [15].
PDs and PKs Oral administration
Immediate release Extended release
Onset of action 10–15 min —
Duration 3–6 h ≤12 h
Distribution Adults: 2.6 L/kg
Children: 2.1 L/kg
Protein binding 38–45%
• Albumin (primarily) and alpha-1-acid glycoprotein
Metabolism In the liver
• By CYP3A4 and CYP3A5 to noroxycodone and then by CYP2D6 to
noroxymorphone. Noroxycodone (active) can also be reduced to alpha or beta
noroxycodol
• By CYP2D6 to oxymorphone and then by CYP3A4 to noroxymorphone
(active). Oxymorphone (active) can also be reduced to alpha or beta
oxymorphol 6-keto-reduced to alpha and beta oxycodol
Bioavailability 60–87%
Half-life elimination 3.2–4 h 4.5–5.6 h
Excretion Urine (mainly)
Table 8.
PDs and PKs of oxycodone at therapeutic doses [21, 45–49].
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about 0.93 mg/L in a single-drug administration and 1.55 mg/L in the combined
drug administration, it is fatal [51]. Common adverse reactions are summarized in
Table 9.
Since oxycodone is an opioid drug, like fentanyl, it has the potential for abuse
and develops tolerance. Repeated use of oxycodone causes the development of
tolerance, which can lead to overdose and death [45–47]. Serious, life-threatening,
or fatal respiratory depression may occur with use of oxycodone orally [45]. Acci-
dental ingestion of even one dose of oxycodone preparations by children can result
in death [47]. Long-term use during pregnancy can result in neonatal opioid with-
drawal syndrome [45]. Concomitant use of oxycodone with CYP3A4 inducers (e.g.,
carbamazepine, phenytoin, and rifampin) may result in increasing clearance and
decreasing plasma concentrations of oxycodone, with possible lack in therapeutic
effectiveness [45]. Concomitant use of oxycodone with CYP3A4 inhibitors may
result in reduced clearance and increased plasma concentrations of oxycodone,
possibly resulting in increased or prolonged opiate effects, including an increased
risk of fatal respiratory depression [52]. These effects could be more pronounced
with concomitant use of oxycodone and inhibitors of both CYP2D6 and CYP3A4
[52]. Population that are particularly at risk and need attention are children; geriat-
ric, cachectic, or debilitated patients; and patients with renal and hepatic impair-
ment, underlying pulmonary conditions, and significant genetic variability in
CYP2D6 activity [45, 53]. There is no evidence to prove hepatotoxicity when used
alone, whereas oxycodone-acetaminophen and other opioid-acetaminophen combi-
nations can lead to acute liver damage caused by unintentional overdose with
acetaminophen [54]. Clinically important DDIs are summarized in Table 10.
Systems Symptoms
CNS Dizziness, drowsiness, headache, fatigue, abnormal dreams, twitching,
abnormality in thinking, agitation, anxiety, chills, depression, hypertonia,
hypoesthesia, insomnia, irritability, confusion, lethargy, nervousness,
paresthesia, neuralgia, personality disorder, withdrawal syndrome
Respiratory Dyspnea, cough, epistaxis, flu-like symptoms, oropharyngeal pain, rhinitis,
sinusitis, pharyngitis, laryngismus, pulmonary disease
Cardiovascular Flushing, tachycardia, palpitations, cardiac failure, deep vein thrombosis,
hypertension/hypotension, edema
GI Constipation, nausea, vomiting, hiccups, upper abdominal pain, abdominal pain,
anorexia, diarrhea, dyspepsia, dysphagia, gingivitis, glossitis, xerostomia,
gastroesophageal reflux, gastritis, gastroenteritis
Hepatic Increased serum alanine aminotransferase
GU Urinary retention, dysuria, urinary tract infection
Ophthalmic Blurred vision, amblyopia
Hematologic and
oncologic
Anemia, leukopenia, neutropenia, thrombocytopenia, hemorrhage
Dermatologic Pruritus, diaphoresis, hyperhidrosis, skin rash, skin photosensitivity,
excoriation, urticaria
Endocrine and
metabolic
Hypochloremia, hyponatremia, hyperglycemia, weight loss, gout
Neuromuscular and
skeletal
Asthenia, arthralgia, ostealgia, back pain, neck pain, limb pain, myalgia, tremor,
arthritis, laryngospasm, pathological fracture
Miscellaneous Hypersensitivity reaction, fever, infection, sepsis, seroma, accidental injury
Table 9.
Common adverse reactions of oxycodone [45–47].
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2.4 Fentanyl, acetaminophen, and oxycodone toxicity, clinical manifestations,
and management
The toxicity, teratogenicity (FDA pregnancy category), and carcinogenicity (by
the International Agency for Research on Cancer), clinical manifestations, and
management of fentanyl, acetaminophen, and oxycodone poisoning are
summarized in Tables 11–13, respectively.
Possible effects Clinically important DDI types
X D C
Increase in the
CNS depressant
effects
Azelastine,
bromperidol,
orphenadrine,
oxomemazine,
paraldehyde,
thalidomide
Blonanserin,
chlormethiazole, CNS
depressants, droperidol,
flunitrazepam, lemborexant,
methotrimeprazine,
perampanel, phenobarbital,
primidone, sodium oxybate,
suvorexant, voriconazole,
zolpidem, CYP3A4
inhibitors (strong)
Alizapride, brimonidine,
bromopride,
tetrahydrocannabinol,
cannabidiol, Cannabis,
dimethindene, dronabinol,
lisuride, lofexidine,
magnesium sulfate,
metoclopramide,
metyrosine, minocycline
(systemic), nabilone,
piribedil, pramipexole,
ropinirole, rotigotine,
rufinamide, CYP3A4
inhibitors (moderate)
Enhancement in
the serotonergic
effects and
serotonin
syndrome
MAOI — Serotonergic agents
Constipation Eluxadoline — Anticholinergic agents,
ramosetron
Urinary
retention
— — Anticholinergic agents
Enhancement in
the bradycardia
effects
— — Succinylcholine
Enhancement in
the psychomotor
impairment
— — SSRI
Table 10.
Oxycodone and clinically important DDIs [15].
Drugs Fentanyl Acetaminophen Oxycodone
LD50 (mouse, i.p.) (mg/kg) 76 367 320
TDLo (human, oral) (mg/kg) 0.1 490 0.14
FDA pregnancy category C C B
Classification by the IARC NA 3 NA
LD50, median lethal dose; TDLo, lowest toxic dose; NA, not assigned [55–63]
Table 11.
Toxicity, teratogenicity, and carcinogenicity of fentanyl, acetaminophen, and oxycodone.
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Drugs Clinical manifestations
Fentanyl Respiratory depression, somnolence, sleepiness, stupor, coma, amnesia, skeletal
muscle flaccidity, cold and clammy skin, constricted pupils, pulmonary edema,
bradycardia, hypotension, partial or complete airway obstruction, atypical snoring,
and death
Acetaminophen Stage I (0.5 to 24 h): nausea, vomiting, diaphoresis, pallor, lethargy, malaise or
asymptomatic
Stage II (24 to 72 h):
• Recovery in stage I symptoms
• Increase in hepatic enzymes (aspartate aminotransferase, alanine
aminotransferase) and total bilirubin, PT elongation, oliguria (occasionally)
Stage III (72 to 96 h):
• Jaundice, hepatic encephalopathy, a marked elevations of hepatic enzymes
(exceed 10,000 IU/L) and total bilirubin (above 4.0 mg/dL), hyperammonemia,
prolongation of the PT/INR, hypoglycemia, lactic acidosis, death (multiorgan
system failure)
Stage IV (4 days to 2 weeks):
• Regression in symptoms and recovery phase
Oxycodone Respiratory depression, sleepiness, stupor, coma, skeletal muscle flaccidity, cold
sweat, constricted pupils, bradycardia, hypotension, QT interval prolongation,
partial or complete airway obstruction, atypical snoring, and death
Table 12.
Clinical manifestations of fentanyl, acetaminophen, and oxycodone poisoning [16, 61, 64–71].
Management
steps
Fentanyl Oxycodone Acetaminophen
ABC Secure airway, breathing, and circulation as necessary
Decontamination
• GI
• Patch
Activated charcoal: within 4 h of ingestion, unless contraindicated
• Adult: 50 g orally
Children: 1 g/kg orally or by nasogastric tube, max. 50 g
• Must be removed
Basic measures
and treatment
1.Ensure adequate ventilation
2.Apply antidotal therapy with NLX. With a
total of 5 to 10 mg, repeat administration
until ventilation is adequate
3.Require supplemental oxygen,
endotracheal intubation, and positive end-
expiratory pressure, if response is
inadequate to NLX or if pulmonary edema
is present
1.Poisoning severity following an
acute ingestion is quantified by
plotting a timed serum
acetaminophen concentration
on the modified Rumack-
Matthew nomogram
2.Antidotal therapy with
N-acetyl cysteine (NAC)
Antidotal
therapy dosing
Adults:
• O2 saturation is <90%: 0.05 mg i.v. or i.m.
• For apneic patients: 0.2 to 1 mg i.v. or i.m.
• Patients in cardiorespiratory arrest: min.
2 mg i.v.
Children:
• <20 kg: 0.1 mg/kg i.v. or intraosseous (i.
o.), max. 2 mg per dose
• ≥20 kg: 2 mg i.v. or i.o.
Adolescents suspected of opioid addiction:
• 0.04 to 0.4 mg per dose repeated every
3–5 min and titrated to patient response
Oral dosing: 140 mg/kg loading
dose, followed by 17 doses of
70 mg/kg every 4 h
21 h i.v. protocol: 150 mg/kg
loading dose over 60 min,
followed by 50 mg/kg infused over
4 h, with the final 100 mg/kg
infused over the remaining 16 h
• INR <2: 21 h i.v. protocol
• INR >2: 21 h i.v. protocol,
followed by a continuous i.v.
NAC infusion at 6.25 mg/kg/h
until INR is <2
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Antidotal therapy with NAC in acetaminophen poisoning should be applied
orally (nonpregnant patients with a functional GI tract and no evidence of hepato-
toxicity) or i.v. (patients with vomiting, contraindications to oral administration,
and hepatic failure) if:
• Serum acetaminophen concentration is above the “treatment” line of the
treatment nomogram
• Serum acetaminophen concentration is unavailable or will not return within
8 h of time of ingestion and acetaminophen ingestion is suspected
• Time of ingestion is unknown and serum acetaminophen level is >10 mcg/mL
(66 μmol/L)
• There is evidence of any hepatotoxicity with a history of acetaminophen
ingestion
• Patient has risk factors for hepatotoxicity, and the serum acetaminophen
concentration is >10 mcg/mL (66 μmol/L) [80–82]
3. Conclusions
Drugs used in the treatment or prevention of diseases can lead to unintentional
or intentional toxicity. Toxicity may be due to high-dose single-drug or multiple-
drug intake. According to the AAPCC 2018 Annual Report, opioid and non-opioid
analgesics often cause single-drug poisoning. The top three of analgesic poisoning
are fentanyl, acetaminophen, and oxycodone, respectively.
Opioid analgesics, such as fentanyl and oxycodone, which are preferred in
severe pain management, show central and peripheral effects by binding to classical
opioid receptors that are widely distributed in the body. Repeated exposure causes
an addiction; higher-dose usage to produce the same effect, i.e. tolerance; and
withdrawal when stopping intake. Therefore, the dose and severity of toxicity differ
between those who take opioid analgesics for the first time and those who are
addicted. In poisoning with opioid analgesics, death due to respiratory depression is
frequently observed. For this reason, in case of poisoning with opioid analgesics,
first of all, adequate ventilation should be provided, subsequent antidote treatment
with naloxone should be applied, the patient should be closely monitored for vital
functions, and appropriate treatment should be performed when necessary. Since
the effect of naloxone is short, application should be repeated when necessary.
Supplementary oxygen, endotracheal intubation, and positive end-expiratory pres-
sure should be considered if adequate response cannot be obtained despite a total of
5 to 10 mg of naloxone. Although high doses are not preferred, toxicity is more
severe in patients using X and D interactive drugs together.
Management
steps
Fentanyl Oxycodone Acetaminophen
Supportive care For possible coma, seizures, hypotension, and
non-cardiogenic pulmonary edema
For vomiting
Table 13.
Management of acute fentanyl, acetaminophen, and oxycodone toxicity [72–82].
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Acetaminophen, a non-opioid analgesic, found in hundreds of prescription and
OTC medicines, with analgesia and antipyretic effects, often causes hepatotoxicity
(hepatic damage, liver failure) or even death. Toxicity develops due to the
overproduction of toxic NAPQI, which occurs during acetaminophen metabolism in
the liver, which quickly consumes the glutathione necessary to convert it to the
nontoxic metabolite and covalently binds to cell proteins and other vital molecules.
Toxicity is more severe in patients with less glucuronidation capacity and/or con-
comitant use of X- and D-type interacting drugs. The use of activated charcoal
within the first 4 h of acetaminophen poisoning and antidote treatment with NAC
successfully heals liver damage.
After stabilizing the patient, it is necessary to investigate whether poisoning is
performed unintentionally or intentionally. If there is substance abuse or suicidal
tendency, the patient should be consulted to a psychiatrist, and psychosocial and/or
medication for addiction treatment should be started. In unintentional poisonings,
adults should be educated/warned by their health protectors about the drugs
(effects, duration of action, daily maximum dose, conditions to be considered, side
effects, and storage conditions) they use for themselves and/or their children, and
additional arrangements should be made to increase the health literacy of the
society. If poisoning has developed due to the X- and D-type interactions of the
drugs used in therapeutic doses, it should be considered to be subject to periodical/
continuous training of health protectors.
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